Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 328

1.

The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome.

Berger BE.

Am J Med Sci. 2016 Aug;352(2):177-90. doi: 10.1016/j.amjms.2016.05.003. Epub 2016 May 9. Review.

PMID:
27524217
2.

Plasmapheresis for the treatment of kidney diseases.

Clark WF, Huang SS, Walsh MW, Farah M, Hildebrand AM, Sontrop JM.

Kidney Int. 2016 Aug 3. pii: S0085-2538(16)30270-8. doi: 10.1016/j.kint.2016.06.009. [Epub ahead of print] Review.

PMID:
27498206
3.

Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review.

Ritchie GE, Fernando M, Goldstein D.

Cancer Chemother Pharmacol. 2016 Aug 6. [Epub ahead of print] Review.

PMID:
27497971
4.

Clinical and Laboratory Consequences of Platelet Transfusion in Shiga Toxin-Mediated Hemolytic Uremic Syndrome.

Beneke J, Sartison A, Kielstein JT, Haller H, Nitschke M, Kunzendorf U, Loos S, Kemper MJ, Stahl RA, Menne J; German 2011 STEC-HUS outbreak study group.

Transfus Med Rev. 2016 Jun 21. pii: S0887-7963(16)30091-8. doi: 10.1016/j.tmrv.2016.06.004. [Epub ahead of print] Review.

PMID:
27468945
5.

Anti-complement-factor H-associated glomerulopathies.

Durey MA, Sinha A, Togarsimalemath SK, Bagga A.

Nat Rev Nephrol. 2016 Sep;12(9):563-78. doi: 10.1038/nrneph.2016.99. Epub 2016 Jul 25. Review.

PMID:
27452363
6.

Cancer-associated thrombotic microangiopathy.

Govind Babu K, Bhat GR.

Ecancermedicalscience. 2016 Jun 28;10:649. doi: 10.3332/ecancer.2016.649. eCollection 2016. Review.

7.

Clinical guides for atypical hemolytic uremic syndrome in Japan.

Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan.

Clin Exp Nephrol. 2016 Aug;20(4):536-43. doi: 10.1007/s10157-016-1276-6. Review.

PMID:
27422619
8.

Self-nonself discrimination by the complement system.

Meri S.

FEBS Lett. 2016 Aug;590(15):2418-34. doi: 10.1002/1873-3468.12284. Epub 2016 Jul 19. Review.

PMID:
27393384
9.

The expanding phenotypic spectra of kidney diseases: insights from genetic studies.

Stokman MF, Renkema KY, Giles RH, Schaefer F, Knoers NV, van Eerde AM.

Nat Rev Nephrol. 2016 Aug;12(8):472-83. doi: 10.1038/nrneph.2016.87. Epub 2016 Jul 4. Review.

PMID:
27374918
10.

Modeling complement-driven diseases in transgenic mice: Values and limitations.

Ueda Y, Gullipalli D, Song WC.

Immunobiology. 2016 Oct;221(10):1080-90. doi: 10.1016/j.imbio.2016.06.007. Epub 2016 Jun 16. Review.

PMID:
27371974
11.

Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.

Risitano AM, Marotta S.

Semin Immunol. 2016 Jun;28(3):223-40. doi: 10.1016/j.smim.2016.05.001. Epub 2016 Jun 23. Review.

PMID:
27346521
12.

Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity.

Beck BB, van Spronsen F, Diepstra A, Berger RM, Kömhoff M.

Pediatr Nephrol. 2016 Jun 11. [Epub ahead of print] Review.

PMID:
27289364
13.

Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer.

Morton JM, George JN.

J Oncol Pract. 2016 Jun;12(6):523-30. doi: 10.1200/JOP.2016.012096. Review.

PMID:
27288467
14.

Genetic Atypical Hemolytic-Uremic Syndrome.

Noris M, Bresin E, Mele C, Remuzzi G.

In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016.
2007 Nov 16 [updated 2016 Jun 9].

15.

Defining the genetics of thrombotic microangiopathies.

Vieira-Martins P, El Sissy C, Bordereau P, Gruber A, Rosain J, Fremeaux-Bacchi V.

Transfus Apher Sci. 2016 Apr;54(2):212-9. doi: 10.1016/j.transci.2016.04.011. Epub 2016 May 2. Review.

PMID:
27177491
16.

The alternative pathway of complement and the thrombotic microangiopathies.

Teoh CW, Riedl M, Licht C.

Transfus Apher Sci. 2016 Apr;54(2):220-31. doi: 10.1016/j.transci.2016.04.012. Epub 2016 Apr 26. Review.

PMID:
27160864
17.

Pregnancy-related thrombotic microangiopathies: Clues from complement biology.

Fakhouri F.

Transfus Apher Sci. 2016 Apr;54(2):199-202. doi: 10.1016/j.transci.2016.04.009. Epub 2016 Apr 25. Review.

PMID:
27158062
18.

Complement and the kidney in the setting of Shiga-toxin hemolytic uremic syndrome, organ transplantation, and C3 glomerulonephritis.

Keir LS, Langman CB.

Transfus Apher Sci. 2016 Apr;54(2):203-11. doi: 10.1016/j.transci.2016.04.010. Epub 2016 Apr 25. Review.

PMID:
27156109
19.

Management of Thrombotic Microangiopathic Hemolytic Anemias with Therapeutic Plasma Exchange: When It Works and When It Does Not.

Mehmood T, Taylor M, Winters JL.

Hematol Oncol Clin North Am. 2016 Jun;30(3):679-94. doi: 10.1016/j.hoc.2016.01.009. Epub 2016 Mar 30. Review.

PMID:
27113004
20.

Critical appraisal of eculizumab for atypical hemolytic uremic syndrome.

Palma LM, Langman CB.

J Blood Med. 2016 Apr 12;7:39-72. doi: 10.2147/JBM.S36249. eCollection 2016. Review.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk